I recently wrote about the patent infringement lawsuit filed by Moderna against Pfizer/BioNTech over the COVID-19 vaccine. In its complaint filed in federal district court in Boston last August, Moderna alleged that Pfizer/BioNTech infringed three of Moderna’s patents in developing the Pfizer/BioNTech COVID-19 vaccine. Moderna seeks damages only for the time period after March 8, 2022, when Moderna announced that it would begin to enforce its patents after holding off doing so for 15 months while the pandemic was raging. The amount of money at stake is high. Pfizer/BioNTech sold over $26.4 billion of the vaccine in the first nine months of 2022; Moderna sold over $13.5 billion of its vaccine during the same time.

Continue Reading The Battle Over the COVID-19 Vaccine Continues

In Bell Semiconductor, LLC v. Omnivision Technologies, Inc., 8-22-cv-01979 (CDCA Mar. 1, 2023)( John A. Kronstadt), the Court granted the Defendant’s motion to dismiss Plaintiff’s indirect patent infringement claims for failure to sufficiently allege Defendant “made” the accused product. Plaintiff had argued that using the patented methods in the design process, which guides the subsequent manufacturing process, is sufficient to state a claim. However, the Court held the Plaintiff provides no authority supporting the contention that the use of a method to design a product is the same as the use of a method to manufacture the product, as contemplated by the statute. 

Continue Reading District Court Finds Use of a Method to Manufacture a Product Does Not Indirectly Infringe a Patented Method to Design A Product

It’s not surprising to hear talk of flowers in February, but it is unusual when that discussion is in a Federal Circuit opinion.  This month the Federal Circuit decided a case involving whether the display of a flowering plant constitutes an invalidating prior public use.

Continue Reading Does Displaying a Flowering Plant Preclude Patenting It?